Dr. Istvan Udvaros joins Cristal Therapeutics as New Chief Medical Officer

Maastricht, The Netherlands, 24 October 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has appointed Dr. Istvan Udvaros as its Chief Medical Officer (CMO) with immediate effect. He will be responsible for the clinical strategy and development of Cristal Therapeutics’ range of nanomedicines, as well as regulatory and medical affairs activities. Dr. Udvaros is a board certified oncologist and brings significant industry and early stage clinical development experience to the Company.

Dr. Udvaros replaces previous CMO Dr. Edwin Klumper.

Welcoming Dr. Udvaros to the team, Dr. Joost Holthuis, Cristal Therapeutics’ CEO and Co- founder said, “We are pleased that someone with Istvan’s track record and experience is joining the Cristal Therapeutics team as Chief Medical Officer. He will be instrumental in supporting our expanding clinical development activities as well as our interactions with key stakeholders, including investigators and the regulatory agencies.”

Commenting on his appointment, Dr. Udvaros added, “Cristal Therapeutics is developing a promising pipeline of targeted CriPec®-based nanomedicines with superior therapeutic profiles. With lead drug candidate CriPec®-docetaxel in clinical Phase 1 studies for the treatment of solid tumours, I am excited to be joining the Company at this key stage of its development.”

Dr. Udvaros joins Cristal Therapeutic from SGS Clinical Research, a CRO based in Mechelen, Belgium, where he held the roles of Executive Medical Director and Project Director of Oncology. Here he had overall responsiblity for the medical, feasibility and organisational aspects of clinical trials and product development.

Previously Dr. Udvaros also worked for six years at PRA Early Development Services as Director of Clinical Operations. His 20-year clinical carreer saw him specialise in ear, nose, and throat along with clinical oncology, where his focus was on head and neck cancer. He is also trained in clinical pharmacology, and received an MD and MSc from the Semmelweis University in Budapest, Hungary.

– Ends –

About Cristal Therapeutics
Cristal Therapeutics is a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need and considerable commercial potential. The Company’s product candidates are based on its proprietary CriPec® polymeric nanoparticle technology platform, which enables the design of customised nanomedicines with superior therapeutic profiles. CriPec®-based products have the potential to provide enhanced efficacy and reduced side effect profiles, thus offering improved disease treatment.

The Company’s lead product, CriPec®-docetaxel, is in clinical Phase I studies for the treatment of solid tumours. The Company has several other products in preclinical development targeting cancer and inflammatory diseases.

Cristal Therapeutics is a private company that has raised over Euro 19M to date. The Company’s headquarters and laboratories are located in Maastricht, The Netherlands.

Find out more: www.cristaltherapeutics.com

For more information, please contact:

Cristal Therapeutics
Joost Holthuis, PhD Chief Executive Officer
Tel: +31 65 435 5535
E: joost.holthuis@cristaltherapeutics.com

Media relations:

Instinctif Partners
Lynne Trowbridge / Eileen Paul / Samantha Cheung Tel: +44 20 7866 7855
E: cristal@instinctif.com